000167838 001__ 167838
000167838 005__ 20240229133550.0
000167838 0247_ $$2doi$$a10.3390/metabo11030129
000167838 0247_ $$2pmid$$apmid:33668370
000167838 0247_ $$2altmetric$$aaltmetric:101372423
000167838 037__ $$aDKFZ-2021-00582
000167838 041__ $$aEnglish
000167838 082__ $$a540
000167838 1001_ $$aOse, Jennifer$$b0
000167838 245__ $$aTargeted Plasma Metabolic Profiles and Risk of Recurrence in Stage II and III Colorectal Cancer Patients: Results from an International Cohort Consortium.
000167838 260__ $$aBasel$$bMDPI$$c2021
000167838 3367_ $$2DRIVER$$aarticle
000167838 3367_ $$2DataCite$$aOutput Types/Journal article
000167838 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1615296488_24578
000167838 3367_ $$2BibTeX$$aARTICLE
000167838 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167838 3367_ $$00$$2EndNote$$aJournal Article
000167838 520__ $$aThe identification of patients at high-risk for colorectal cancer (CRC) recurrence remains an unmet clinical need. The aim of this study was to investigate associations of metabolites with risk of recurrence in stage II/III CRC patients. A targeted metabolomics assay (128 metabolites measured) was performed on pre-surgery collected EDTA plasma samples from n = 440 newly diagnosed stage II/III CRC patients. Patients have been recruited from four prospective cohort studies as part of an international consortium: Metabolomic profiles throughout the continuum of CRC (MetaboCCC). Cox proportional hazard models were computed to investigate associations of metabolites with recurrence, adjusted for age, sex, tumor stage, tumor site, body mass index, and cohort; false discovery rate (FDR) was used to account for multiple testing. Sixty-nine patients (15%) had a recurrence after a median follow-up time of 20 months. We identified 13 metabolites that were nominally associated with a reduced risk of recurrence. None of the associations were statistically significant after controlling for multiple testing. Pathway topology analyses did not reveal statistically significant associations between recurrence and alterations in metabolic pathways (e.g., sphingolipid metabolism p = 0.04; pFDR = 1.00). To conclude, we did not observe statistically significant associations between metabolites and CRC recurrence using a well-established metabolomics assay. The observed results require follow-up in larger studies.
000167838 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000167838 588__ $$aDataset connected to CrossRef, PubMed,
000167838 650_7 $$2Other$$acolorectal cancer
000167838 650_7 $$2Other$$arecurrence
000167838 650_7 $$2Other$$atargeted metabolomics
000167838 7001_ $$aGigic, Biljana$$b1
000167838 7001_ $$00000-0001-5238-6900$$aBrezina, Stefanie$$b2
000167838 7001_ $$aLin, Tengda$$b3
000167838 7001_ $$00000-0002-5329-9507$$aBaierl, Andreas$$b4
000167838 7001_ $$aGeijsen, Anne J M R$$b5
000167838 7001_ $$00000-0002-9402-2029$$avan Roekel, Eline$$b6
000167838 7001_ $$00000-0002-2532-1455$$aRobinot, Nivonirina$$b7
000167838 7001_ $$aGicquiau, Audrey$$b8
000167838 7001_ $$aAchaintre, David$$b9
000167838 7001_ $$aKeski-Rahkonen, Pekka$$b10
000167838 7001_ $$aDuijnhoven, Fränzel J B van$$b11
000167838 7001_ $$00000-0001-9319-5350$$aGumpenberger, Tanja$$b12
000167838 7001_ $$00000-0001-8001-8793$$aHolowatyj, Andreana N$$b13
000167838 7001_ $$00000-0001-7154-8207$$aKok, Dieuwertje E$$b14
000167838 7001_ $$00000-0002-9927-9034$$aKoole, Annaleen$$b15
000167838 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b16$$udkfz
000167838 7001_ $$aUlrich, Alexis B$$b17
000167838 7001_ $$aSchneider, Martin$$b18
000167838 7001_ $$aUlvik, Arve$$b19
000167838 7001_ $$aUeland, Per-Magne$$b20
000167838 7001_ $$aWeijenberg, Matty P$$b21
000167838 7001_ $$aHabermann, Nina$$b22
000167838 7001_ $$00000-0001-6651-6710$$aScalbert, Augustin$$b23
000167838 7001_ $$00000-0002-9795-1528$$aGsur, Andrea$$b24
000167838 7001_ $$00000-0001-7641-059X$$aM Ulrich, Cornelia$$b25
000167838 773__ $$0PERI:(DE-600)2662251-8$$a10.3390/metabo11030129$$gVol. 11, no. 3, p. 129 -$$n3$$p129$$tMetabolites$$v11$$x2218-1989$$y2021
000167838 909CO $$ooai:inrepo02.dkfz.de:167838$$pVDB
000167838 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000167838 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000167838 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000167838 9141_ $$y2021
000167838 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMETABOLITES : 2018$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-08-25
000167838 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-25
000167838 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-25
000167838 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000167838 980__ $$ajournal
000167838 980__ $$aVDB
000167838 980__ $$aI:(DE-He78)C120-20160331
000167838 980__ $$aUNRESTRICTED